new glp 1 agonist novo nordisk Nordisk's weight-loss pill wins FDA approval Novo Nordisk GLP-1 Drug Meets
Description
Meier 2012)
In general, DPP-4 inhibitors are effective at promoting moderate lowering of A1C and are associated with few adverse events
doi: 10.1139/apnm-2020-0005
Children 12 or older can take it if they are at or above the 95th weight percentile for their sex and age
What youll learn: Most GLP-1 receptor agonist medications are taken as daily or weekly injections
With "Retatrutide vs tirzepatide," the difference lies in its additional action on glucagon
